LLY-DERM’s 2% premium is only the second biotech buyout (AFAIK) valued at $1B+ with a premium that small. The other case was JAZZ-GENT in 2013: https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-gentium-spa-announce-agreement-for-jazz-pharmaceuticals-to-acquire-gentium-for-5700-per-share-236619511.html https://investorshub.advfn.com/boards/read_msg.aspx?message_id=95143526